# Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

> **NCT01591577** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Newly Diagnosed Glioblastoma Multiforme

## Interventions

- **OTHER:** Lapatinib/Temozolomide/radiation

## Key facts

- **NCT ID:** NCT01591577
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-07
- **Primary completion:** 2024-05-07
- **Final completion:** 2024-05-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591577, "Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01591577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*